Cargando…

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment

During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research pap...

Descripción completa

Detalles Bibliográficos
Autor principal: Kast, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313620/
https://www.ncbi.nlm.nih.gov/pubmed/30274295
http://dx.doi.org/10.3390/medsci6040084
_version_ 1783383974976946176
author Kast, Richard E.
author_facet Kast, Richard E.
author_sort Kast, Richard E.
collection PubMed
description During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research papers appeared that are crucial to our understanding of glioblastoma vis-a-vis the mode of action of bevacizumab. As a consequence of these papers, a new, potentially more effective treatment protocol can be built around bevacizumab. This is the ADZT regimen, where four old drugs are added to bevacizumab. These four drugs are apremilast, marketed to treat psoriasis, dapsone, marketed to treat Hansen’s disease, zonisamide, marketed to treat seizures, and telmisartan, marketed to treat hypertension. The ancillary attributes of each of these drugs have been shown to augment bevacizumab. This paper details the research data supporting this contention. Phase three testing of AZDT addition to bevacizumab is required to establish safety and effectiveness before general use.
format Online
Article
Text
id pubmed-6313620
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63136202019-01-04 Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment Kast, Richard E. Med Sci (Basel) Concept Paper During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research papers appeared that are crucial to our understanding of glioblastoma vis-a-vis the mode of action of bevacizumab. As a consequence of these papers, a new, potentially more effective treatment protocol can be built around bevacizumab. This is the ADZT regimen, where four old drugs are added to bevacizumab. These four drugs are apremilast, marketed to treat psoriasis, dapsone, marketed to treat Hansen’s disease, zonisamide, marketed to treat seizures, and telmisartan, marketed to treat hypertension. The ancillary attributes of each of these drugs have been shown to augment bevacizumab. This paper details the research data supporting this contention. Phase three testing of AZDT addition to bevacizumab is required to establish safety and effectiveness before general use. MDPI 2018-09-29 /pmc/articles/PMC6313620/ /pubmed/30274295 http://dx.doi.org/10.3390/medsci6040084 Text en © 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Concept Paper
Kast, Richard E.
Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
title Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
title_full Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
title_fullStr Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
title_full_unstemmed Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
title_short Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
title_sort paths for improving bevacizumab available in 2018: the adzt regimen for better glioblastoma treatment
topic Concept Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313620/
https://www.ncbi.nlm.nih.gov/pubmed/30274295
http://dx.doi.org/10.3390/medsci6040084
work_keys_str_mv AT kastricharde pathsforimprovingbevacizumabavailablein2018theadztregimenforbetterglioblastomatreatment